Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023423 · ClinicalTrials.gov registry record · Phase 1
A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT03023423 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 100 participants.
The verdict
NCT03023423, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.
Interventions
- DRUG Atezolizumab
- DRUG Daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-12-23 |
| Est. Completion | 2019-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03023423
The ClinicalTrials.gov registry entry for NCT03023423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03023423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03023423 about?
NCT03023423 is a clinical study titled "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer". The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.
What is the current status of trial NCT03023423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2016-12-23. Estimated completion is 2019-09-26.
What interventions are being tested in trial NCT03023423?
The interventions under investigation include: Atezolizumab (DRUG), Daratumumab (DRUG).
Who is sponsoring clinical trial NCT03023423?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.